WATERTOWN, Mass. Jan. 04, 2024 - C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, has successfully finalized a significant milestone in its mission to revolutionize disease treatment. Today, C4 Therapeutics proudly announced the completion of its $25 million stock purchase agreement with an esteemed subsidiary of Betta Pharmaceuticals Co. Ltd (Betta) (300558.SZ), a renowned Chinese pharmaceutical company specializing in innovative oncology therapies. This strategic financial influx has been marked at an impressive $4.49 per share, representing a remarkable 25% premium over the 60-trading-day volume weighted average as of May 29, 2023, two business days prior to the agreement’s execution.
The closing of this equity investment between C4 Therapeutics and Betta Pharmaceuticals showcases a powerful partnership to advance the groundbreaking field of targeted protein degradation, challenging the conventional approaches to uncovering effective treatments for various diseases. Through this collaboration, C4 Therapeutics aims to develop a new generation of small-molecule medicines, revolutionizing the world of biopharmaceuticals and transforming how diseases are treated.
C4 Therapeutics’ dedication to advancing targeted protein degradation science positions them as a leading contributor in the biopharmaceutical industry. With their innovative approach, C4 Therapeutics aims to refine and enhance current treatment options, ultimately improving patient outcomes and quality of life.
Betta Pharmaceuticals, known for their commitment to developing innovative oncology therapies, recognizes the potential in C4 Therapeutics to disrupt the healthcare landscape with their revolutionary approach. This strategic equity investment not only represents Betta Pharmaceuticals’ confidence in C4 Therapeutics’ potential but also serves as a testament to their mutual commitment to drive forward groundbreaking advancements for patients in need.
The $25 million equity investment by Betta Pharmaceuticals highlights the promising future for C4 Therapeutics. This financial injection will be instrumental in furthering the company’s research and development efforts while accelerating the progress of its proprietary platform technology. The partnership between these two pharmaceutical powerhouses significantly strengthens C4 Therapeutics’ position within the industry, propelling them to the forefront of targeted protein degradation science.
Through this landmark $25 million equity investment, both C4 Therapeutics and Betta Pharmaceuticals reaffirm their shared mission to revolutionize disease treatment. By combining their expertise and resources, they are poised to disrupt the status quo and uncover groundbreaking solutions that will provide hope and improved outcomes for patients worldwide.
In conclusion, the closing of the $25 million equity investment by Betta Pharmaceuticals solidifies C4 Therapeutics’ position as an innovative force within the biopharmaceutical industry. This strategic collaboration between the two companies sets the stage for transformative advancements in targeted protein degradation and ultimately, a new era of disease treatment. Together, C4 Therapeutics and Betta Pharmaceuticals are blazing a trail towards a brighter future, where effective and personalized medicines hold the key to unlocking better health for all.
Comments